Innovations

Found results: 1005

Innovative Russia

Entrepreneurial competition "Business of Innovative Technologies" (BIT-2008)

Make the investor believe in you! Under this motto, the Business of Innovative Technologies Business competition is being held in Russia for the fifth time. Its goal is to initiate the creation of new technology companies and promote the development of a culture of entrepreneurship in the Russian high tech sector.

11.07.2008
Innovative Russia

The breakthrough into the future, apparently, is postponed

Biotechnologies in the Russian Federation are practically not developing, stated at the forum the director of the center "Bioengineering" of the Russian Academy of Sciences K.Scriabin. Investing money in the areas listed by him will be in demand in the market and will bring returns. So, the introduction of genetic analysis for artificial insemination in the capital and in St. Petersburg could generate income of up to $ 30 million. "Apparently, there are people who are interested that we do not have this," the well-known scientist noted.

11.07.2008
Biotechnologies - into life

Biotechnology in Russia: hope is not lost yet

Even under the optimistic scenario, by 2010 Russia will produce only 0.25% of the global volume of biotechnological products. But the authors of the article continue to convince readers that Russia is still capable of not only joining the global biotech race, but also rapidly advancing in the main areas of breakthrough. If everyone votes for United Russia...

11.07.2008
Biotechnologies - into life

Development of biotechnology: Lithuanian scenario

In 2006, a dozen and a half enterprises and institutions signed an agreement on the establishment of the Lithuanian National Biotechnology Platform, which assumed the mission of combining science and production with the prospect of its transformation into an industrial industry.

11.07.2008
Biotechnologies - into life

Development of a regulatory framework for cellular technologies: USA, EU, WHO

Most types of tissue and cell transplantation in the world are going through the initial stage of their formation. Thus, in the USA and the EU, the use of stem cells (with the exception of bone marrow progenitor cells) is limited only to the initial stages of clinical trials involving a small number of patients. In many countries of the world, with the participation of WHO, scientific and expert potential is being concentrated to regulate this kind of activity, regulatory legal acts are being created.

11.07.2008
Biotechnologies - into life

Let's get to work. For the living

Living systems are the second (after nanotechnology) direction, which is actively supported by the state. A lot of money is allocated for the development of this sector of sciences. There are intelligent authors. There are original ideas. Unfortunately, they are not very popular on the market yet.

11.07.2008
Biotechnologies - into life

Neuroscience and public investment

In 2005, the Department of Neurodynamics and Neurobiology was opened at Nizhny Novgorod State University. When the university received a large grant within the framework of the national project “Education”, an amount equivalent to one million euros was allocated to our department. With this money, we are forming an educational neuroscience laboratory, which will be equipped with modern equipment, which currently has no analogues in Russia.

11.07.2008
Biotechnologies - into life

How Danone Turns Bacteria into Bucks

The main talent of the French is the transformation of bacteria into bucks! They used the most advanced scientific developments to identify microorganisms that contribute to improving a person's well-being and even the freshness of his appearance.

11.07.2008
Biotechnologies - into life

Biotechnology on lease

The effectiveness of leasing becomes obvious if the process of obtaining a certain resource is decomposed into components.

11.07.2008
Biotechnologies - into life

Business Angel for sliced DNA

To understand the revolutionary nature of the new technology, it is enough to give a simple example: to measure the concentration of an antibiotic in the blood by traditional methods, it will take two days, and the use of abnormal optical activity of DNA scraps turned into a liquid crystal will reduce this time to ten minutes.

11.07.2008
Note to the businessman

Activation of protomitochondria is the path to cell rejuvenation

A curious research project is under consideration at the Eternal Youth Foundation. The data obtained by the author as a result of previous studies supported by the RFBR grant allow us to count on the development of ways to treat mitochondrial encephalomyopathies and slow down and even prevent the aging processes of cells induced by damage to their active oxygen forms by activating the growth of protomitochondria, as well as the elimination of old mitochondrial organelles – postmitochondria.

11.07.2008
Note to the businessman

Stock market 2008 – "hot" five

Fortune magazine included GlaxoSmithKline, one of the world's largest pharmaceutical companies intensively engaged in the development and production of biotechnological drugs, and one Russian company in the top five in terms of investment attractiveness for next year: (true, it has nothing to do with biotech and biopharma):

11.07.2008
Note to the businessman

How to make money on IPO expectations

The statistics of the Russian IPO market show that the shares of most companies fall in price after the initial public offering. Meanwhile, in the process of preparing for the IPO, issuers are restructuring, becoming transparent, and their value is growing rapidly. To participate in the growth that precedes the placement of shares, so-called pre-IPO funds are used.

11.07.2008
Note to the businessman

Pharmaceutical industry: waiting for a deadlock

Competition from generic drugs (copies of original drugs) will lead to a reduction in sales of the largest American companies by $67 billion already in 2007-2012, as patent protection for more than 30 drugs will expire. This is almost half of the total revenue of US companies in 2007. Looking at all this, financial analysts do not recommend investing in the securities of pharmaceutical companies. Experts predict the leadership of biotechnologies, in which generics are technologically and legally impossible.

11.07.2008